Cure My Disease

Don't miss your cure!

 Log in / Sign up

Timing is everything: new trial seeks to boost cancer treatment by scheduling immunotherapy just right

NCT ID NCT07388836

Disease control Sponsor: Fujian Cancer Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase II trial tests whether giving the immunotherapy drug toripalimab on different days during chemotherapy can improve outcomes for people with advanced nasopharyngeal cancer. About 198 participants will receive standard chemotherapy plus toripalimab on Day 1, Day 5, or Day 9 of each 3-week cycle. The main goal is to see which timing leads to the highest rate of complete tumor disappearance after two cycles.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Toripalimab (an immunotherapy drug) combined with gemcitabine and cisplatin chemotherapy
What this could lead to
If successful, this could identify the best timing for adding immunotherapy to chemotherapy, potentially improving tumor shrinkage and long-term control for patients with advanced nasopharyngeal cancer.
What could go wrong
This is an early-phase (Phase II) trial with only 198 participants, so results may not apply to all patients. The study is not yet recruiting, and the optimal timing may not improve outcomes or could increase side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 198 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age between 18 and 70 years Histologically confirmed locoregionally advanced nasopharyngeal carcinoma (AJCC/UICC 8th edition stage II-III) At least one measurable target lesion per RECIST 1.1 ECOG performance status of 0-1 Estimated life expectancy ≥ 6 months Adequate hematologic, hepatic, renal, and coagulation function Negative pregnancy test for women of childbearing potential Willingness to use effective contraception during the study and for 12 months after treatment Signed informed consent Willing and able to comply with study procedures Not participating in any other interventional clinical trials during the study period Exclusion Criteria: * re first dose Active or suspected autoimmune disease requiring systemic treatment Ongoing systemic immunosuppressive therapy Active hepatitis B, hepatitis C, HIV infection, or other serious infections History of another malignancy within 5 years (except non-melanoma skin cancer or in situ cervical cancer) Pregnant or breastfeeding women Inability or unwillingness to use contraception as required Life expectancy \< 6 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Locally advanced nasopharyngeal carcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Locally advanced nasopharyngeal carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.